NASDAQ:GRFS - GRIFOLS S A/S Stock Price, News, & Analysis

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

GRIFOLS S A/S announced a special dividend on Thursday, November 8th. Stockholders of record on Monday, December 3rd will be paid a dividend of $0.2283 per share on Tuesday, December 11th. This represents a dividend yield of 2.25%. The ex-dividend date is Friday, November 30th. This is a positive change from GRIFOLS S A/S's previous special dividend of $0.01. View GRIFOLS S A/S's Dividend History.

Shares of GRIFOLS S A/S split on the morning of Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were issued to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

GRIFOLS S A/S is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for GRIFOLS S A/S.

7 analysts have issued 12-month target prices for GRIFOLS S A/S's stock. Their predictions range from $19.00 to $19.00. On average, they anticipate GRIFOLS S A/S's stock price to reach $19.00 in the next twelve months. This suggests that the stock has a possible downside of 1.2%. View Analyst Price Targets for GRIFOLS S A/S.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GRIFOLS S A/S.

Press coverage about GRFS stock has trended neutral on Friday, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GRIFOLS S A/S earned a news sentiment score of 0.5 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the near future.

Some companies that are related to GRIFOLS S A/S include Allergan (AGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Zoetis (ZTS), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF) and Genmab A/S (GNMSF).

GRIFOLS S A/S's stock is owned by a number of of retail and institutional investors. Top institutional investors include Cardinal Capital Management (0.00%), Moody National Bank Trust Division (0.00%) and Quadrant Capital Group LLC (0.00%).

GRFS stock was purchased by a variety of institutional investors in the last quarter, including Quadrant Capital Group LLC, Cardinal Capital Management and Moody National Bank Trust Division.

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of GRFS stock can currently be purchased for approximately $19.24.

GRIFOLS S A/S has a market capitalization of $13.04 billion and generates $4.88 billion in revenue each year. The biotechnology company earns $749.04 million in net income (profit) each year or $1.10 on an earnings per share basis. GRIFOLS S A/S employs 18,296 workers across the globe.

The official website for GRIFOLS S A/S is http://www.grifols.com.

GRIFOLS S A/S's mailing address is AVINGUDA DE LA GENERALITAT 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 34-93-571-2200 or via email at [email protected]